techMARK (TASX)

4,537.03
   
  • Change Today:
      36.69
  • 52 Week High: 4,754.14
  • 52 Week Low: 3,951.85

AstraZeneca receives 'positive' results from trial on amyloid polyneuropathy drug

By Iain Gilbert

Date: Tuesday 21 Jun 2022

LONDON (ShareCast) - (Sharecast News) - Drugmaker AstraZeneca has received positive high-level results from an interim analysis of its NEURO-TTRansform Phase III trial on eplontersen, the group's hereditary transthyretin-mediated amyloid polyneuropathy drug candidate.
AstraZeneca said on Tuesday that analysis of the study had revealed eplontersen had met its co-primary and secondary endpoints, reaching a "statistically significant and clinically meaningful" improvement in the percentage change of serum transthyretin concentration, and also met its co-primary endpoint of change in the modified neuropathy impairment score - a measure of neuropathic disease progression.

The FTSE 100-listed firm added that the high-level results also showed the trial had reached its secondary endpoint of change from baseline in the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy, indicating that treatment with eplontersen had "significantly" improved patient-reported quality of life.

"These promising results show eplontersen has the potential to be a new and much-needed treatment where limited options exist and significant unmet medical need remains," said AZN.

Based on the 35-week interim trial results, AZN and its partner Ionis will seek regulatory approval for eplontersen and plan to file a new drug application with the Food and Drug Administration in 2022.

As of 0845 BST, AstraZeneca shares were up 0.14% at 10,068.0p.



Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Price Data

Price 4,537.03
Change Today 36.69
% Change 0.82 %
28-Mar-24 Close 4,537.03

Top Risers

Price Change
SPT 200.00p +11.7%
XAR 106.00p +3.4%
XPP 1,090.00p +2.8%
OXIG 2,125.00p +2.4%
RSW 4,250.00p +2.4%
BVC 19.43p +2.0%
RCDO 457.00p +2.0%
OXB 201.00p +1.9%
RM. 54.90p +1.9%
VOD 70.46p +1.5%

Top Fallers

Price Change
SN. 991.60p -5.0%
GNS 1,765.00p -1.2%
BA. 1,349.50p -0.3%

Top of Page